PMH48 BETTER PERSISTENCE ONTREATMENT WITH ESCITALOPRAM COMPARED WITH CITALOPRAM  by Ereshefsky, L et al.
the cost is covered by public payers, a sizable proportion (33–
37%) of the hospitalizations for bipolar disorder, depression, and
substance use disorders are covered by private payers.
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OBJECTIVE: This study evaluated antipsychotic use in Medic-
aid beneﬁciaries with a schizophrenic disorder and identiﬁed
factors associated with poor adherence. METHODS: This study
involved a retrospective cohort analysis of non-dual Florida
Medicaid recipients who had a medical claim indicating a
schizophrenic disorder (ICD-9-CM 295.XX) and received an
antipsychotic (APS) medication between July 1, 2004 and June
30, 2005. Patients were followed for one year after the ﬁrst APS
prescription. Adherence was measured using the Medication
Possession Ratio (MPR: deﬁned as unduplicated ambulatory
treatment days divided by the number of ambulatory days in the
period), medication persistence (days between the ﬁrst and last
antipsychotic in the follow-up period), and number of untreated
days. Logistic regression models were used to identify predictors
of poor adherence (MPR < 0.80). RESULTS: A total of 8828
patients met inclusion criteria. Mean (SD) age was 42.3
(13.7) years, 49% were female, and 36.8% were white.
Approximately 18% and 39% had pre-existing diagnoses of
substance abuse or other psychiatric conditions, respectively.
Mean (SD) MPR was 0.72 (0.3). The mean number of
untreated days was 47.4 (60.8), and mean persistence was
311.9 (102.5) days. Approximately 57% of patients had MPR
values between 0.8 and 1. Logistic regression indicated that
younger patients (<18 years), females, nonwhites, those with a
substance abuse diagnosis or who received antidepressants, and
those newly starting APS therapy were signiﬁcantly more likely
to be poorly adherent, while those treated with atypical or
injectable antipsychotics (vs. conventional orals) were less likely
to be poorly adherent. CONCLUSION: Several patient charac-
teristics are predictive of poor adherence to APS therapy. Study
ﬁndings may be informative to health plan administrators inter-
ested in identifying patients at risk for medication non-
adherence.
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OBJECTIVE: To examine the impact of antipsychotic medica-
tion adherence on outcomes among individuals diagnosed with
bipolar disorder. METHODS: An administrative claims data-
base for a commercially-insured population was used to identify
patients with bipolar disorder who were newly initiating treat-
ment with antipsychotics (January 2000–December 2006).
Patients were included if they were aged between 18–64 years,
had no diagnoses of dementia or schizophrenia, and were con-
tinuously insured from 6 months prior through 12 months post-
index date (N = 7769). Logistic stepwise regressions examined
the association between achievement of adherence goals and
patient outcomes (hospitalization or emergency room (ER) visit
for any reason, mental-health related hospitalizations or ER
visit), while controlling for demographic characteristics, type of
bipolar disorder, general health, and comorbidities. Adherence
was measured by the medication possession ratio (MPR).
RESULTS: The mean MPR was 41.65%, with 61.68% of indi-
viduals having an MPR of less than 0.50 and 78.67% having an
MPR of less than 0.75. A signiﬁcant reduction in the risk of
hospitalization (odds ratio [OR = 0.854]; 95% CI: 0.746–0.978)
or an ER visit for any cause (OR = 0.843; 95% CI: 0.744–0.955)
was associated with an MPR of 0.75 or more. An MPR of 0.80
or more was associated with a signiﬁcant reduction in the risk of
a mental-health related hospitalization (OR = 0.817; 95% CI:
0.699–0.954) while an MPR of 0.90 or more was associated with
a signiﬁcant reduction in the risk of a mental-health related
ER visit (OR = 0.705; 95% CI: 0.544–0.912). Incremental im-
provements in MPR from 0.75 to 0.95 were associated with
corresponding reductions (20 to 30%) in the risk of any hospi-
talization or ER visit. CONCLUSION: As medication adherence
improved, risk of hospitalization or ER visit declined, illustrating
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OBJECTIVE: Guidelines recommend use of antidepressants for a
minimum of six months in major depressive disorder in order to
decrease the risk of relapse. Persistence on treatment depends
both on efﬁcacy and tolerability. In clinical trials, escitalopram
has shown a better efﬁcacy and equivalent tolerability compared
with citalopram. This work compares persistence on treatment
at six months and associated economic consequences, for treat-
ment with escitalopram vs. citalopram. METHODS: Using US
denominator-based claims database PharMetrics (includes data
from 86 managed care health plans covering 45 million patients),
we included adult patients diagnosed with depression who
started escitalopram or citalopram between January 1, 2003 and
December 31, 2004. Six-months persistence was deﬁned as the
percentage of patients still on treatment at 6 months. We com-
pared persistence over time using Cox model, and health care
costs at 6 months using log-linear regression. Propensity scoring
was used to account for channelling by indication. RESULTS:
A total of 13,227 patients started escitalopram; 3,624 pa-
tients started citalopram. Persistence at 6 months was 20.4%
with escitalopram vs. 16.2% with citalopram (p < 0.001).
Escitalopram-treated patients were more likely to be persistent
over 6-months than citalopram-treated patients adjusted for their
baseline characteristics (HR = 0.896; 95%CI = [0.859–0.934]).
More were observed on citalopram than on escitalopram (7.8 vs.
6.2; p < 0.001). Total health care costs over 6-months (including
treatment cost) were non-signiﬁcantly lower for escitalopram-
treated patients than for citalopram-treated patients (-USD232
per patient; p = 0.2). Persisters at 6 months incurred less total
health care costs than non-persisters (-USD280 over the 6
months). CONCLUSION: Persistence at 6 months is higher on
escitalopram than on citalopram, in consistency with its better
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efﬁcacy proﬁle. Persistence at 6 months is recommended to maxi-
mise chances of sustained remission and to avoid relapse; inter-
estingly these results show that persistence is also associated with
decreased health care costs. Efforts should be made to promote
persistence on antidepressant treatment.
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OBJECTIVE: Two-month head-to-head clinical trials of escitalo-
pram and venlafaxine demonstrated similar efﬁcacy and better
tolerability for escitalopram. As routine practice may differ from
controlled trial, policy makers wonder how clinical trial ﬁndings
translate into real life outcomes in community practice. This
work compares early treatment discontinuation (ETD) rates at 1
and 2 months and its economic consequences at 6 months, for
patients with depression treated with venlafaxine and escitalo-
pram. METHODS: Using US denominator-based claims data-
base PharMetrics (includes data from 86 managed care health
plans covering 45 million patients), we included adult patients
diagnosed with depression who started venlafaxine or escitalo-
pram between January 1, and December 31, 2004. We compared
ETD at 1 and 2 months using Cox proportional hazard models
and health care costs at 6 months, using log-linear regression.
Propensity scoring was used to account for channelling by indi-
cation. RESULTS: A total of 13,227 patients started escitalo-
pram; 5,922 patients started venlafaxine. ETD at 2 months was
47% for venlafaxine, 45% for escitalopram. At 1 month, ven-
lafaxine patients had a 50% greater risk of ETD than escitalo-
pram patients (Hazard Ratio = 0.493 [95%CI 0.432–0.564]);
this difference decreased at 2 months (Hazard Ratio = 0.955
[95%CI 0.912–0.999]). Six-month health care costs were higher
with venlafaxine (+USD626, p < 0,01). Patients continuing treat-
ment at 2 months had 36% chance of still being on treatment
at 6 months. Patients (all treatments) with ETD at 2 months
incurred more costs over 6 months (+USD350) compared to
patients continuing treatments. CONCLUSION: Early treatment
discontinuation rate was higher with venlafaxine than escitalo-
pram, possibly due to intolerance to venlafaxine. Absence of
ETD was associated with long term persistence and lower total
treatment costs.
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OBJECTIVE: Patients with bipolar disorder are often poorly
medication adherent, resulting in deteriorating symptomology,
higher admission rates, and diminished quality of life. Many
factors are strongly associated with adherence, including ﬁnan-
cial burdens and multiple psychosocial barriers. However, analy-
ses typically consider these barriers independently rather than
conjointly from the patient’s perspective. Such approaches
neglect the complex interplay of risk factors, many of which are
amenable to health policy or clinical interventions. This study
evaluates the differential and cumulative impact of nine barriers
upon medication adherence. METHODS: We recruited 435
patients from the Continuous Improvement for Veterans in
Care—Mood Disorders study (FY04–06). Surveys collected
information on multiple adherence barriers: medication copay-
ments, foregoing treatment due to cost, binge drinking, access
difﬁculty, social support problems, poor therapeutic alliance, and
low medication insight. Multivariable logistic regression
modeled adherence as a function of perceived adherence barriers,
controlling for demographics, homelessness, and affective symp-
tomology. RESULTS: Nearly half of the respondents reported
adherence difﬁculty. Patients experienced an average of 2.8 bar-
riers, with 41% perceiving at least 3. Minority veterans reported
poorer adherence than white patients (56% versus 40%, p =
.01), while claiming more overall barriers, particularly ﬁnancial
burden, binge drinking, and difﬁculty obtaining psychiatric care
when needed. Multivariable models indicated the total number
of barriers was signiﬁcantly associated with poor adherence
(OR = 1.24 per barrier). The most signiﬁcant were low medica-
tion insight, binge drinking, and problems accessing care (ORs of
2.41, 1.95 and 1.73, respectively). CONCLUSION: Veterans
with bipolar disorder experience multiple barriers to medication
adherence, a scenario possibly exacerbated by recent copayment
increases. Certain psychosocial and ﬁnancial obstacles proved
especially pernicious in connection to worse adherence. Recog-
nizing multiple barriers can assist developing tailored clinical
interventions to improve poor adherence by reducing psychoso-
cial risk factors. The interaction with health beneﬁt polices
potentially contributes to burdens faced by patients already expe-
riencing adherence problems.
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OBJECTIVE: The objectives of this study are to describe and
deﬁne a new adherence measure, the Daily Possession Ratio
(DPR), and to contrast that measure with two variants of
the Medication Possession Ratio (MPR, truncated MPR).
METHODS: This study was a retrospective analysis of the North
Carolina Medicaid administrative claims data from July 1999 to
June 2000. Data for non-HMO, non-hospitalized, non-pregnant
schizophrenia patients (ICD-9-CM = 295.**) with at least one
antipsychotic were aggregated to the person-quarter level. The
daily possession ratio was deﬁned as the number of days one or
more antipsychotics was available divided by the total days in the
quarter. Adherence rates were also estimated for subjects that
switched medications or had therapeutic duplication in the
quarter. RESULTS: The ﬁnal sample consisted of 25,200 person-
quarters from 7,069 individuals. For person quarters with single
antipsychotic use, adherence to antipsychotics as a class was:
DPR = 0.607; truncated MPR = 0.640; MPR = 0.695 (p <
0.0001). For person quarters with therapeutic duplication, the
following adherence measures were observed: DPR = 0.669;
truncated MPR = 0.774; MPR = 1.238 (p < 0.0001). CONCLU-
SION: The DPR provides a more conservative estimate of adher-
ence than the MPR across all type of users, however the
differences between the two methods are more substantial for
persons switching therapy and prescribed therapeutic duplica-
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